Pure Global
NCT01470313

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE)
Pfizer·Phase 1·ClinicalTrials.gov·drugTerminated
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cutaneous Lupus Erythematosus
Drug/Device/Intervention
PD-0360324
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Pfizer
Location
Anniston,Oxford,Los Angeles,Orange Park,Chicago,Indianapolis,Fort Gratiot,Charlotte,Ducansville,Philadelphia,Wyomissing,Rapid City,Rapid City,Jackson,Dallas,Norfolk,Clarksburg,Markham,Chisinau, Canada,Moldova - Republic of,United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Nov 01, 2011
End date
Nov 01, 2013
Enrollment
28 participants
Primary outcome

Safety and tolerability of PD- 0360324 will be assessed by physical examinations, adverse event and infection monitoring, 12 lead ECGs, vital sign, and clinical safety laboratory measurements.

Summary

This study is designed to evaluate the safety and tolerability of multiple intravenously
 administered doses of PD-0360324 in patients with cutaneous lupus erythematosus. Changes in
 disease activity will also be evaluated.

ICD-10 classifications
Subacute cutaneous lupus erythematosusLupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosusSystemic lupus erythematosus, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01470313
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01470313 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pfizer and is currently Terminated. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.